{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005150","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.904244+00:00","generated_at":"2026-06-17T09:08:15.545853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fortress Biotech reports record FY2022 revenue $75.7M, net loss $(86.6)M; BLA accepted for cosibelimab","bullets":["Record consolidated net revenue of $75.7M for FY2022, up from $68.8M in FY2021; $71.0M from dermatology products.","GAAP net loss attributable to common stockholders of $(86.6)M ($(0.97)/share) vs $(64.7)M ($(0.79)/share) in FY2021.","Cash, equivalents and restricted cash $181.0M at Dec 31, 2022, down from $308.0M at Dec 31, 2021.","FDA accepted BLA for cosibelimab (anti-PD-L1) for cSCC; PDUFA goal date Jan 3, 2024; no advisory committee planned.","Expects to complete rolling NDA for CUTX-101 (Menkes disease) and submit NDA for DFD-29 (rosacea) in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005150","json":"https://secwatch.observer/filing/0001558370-23-005150.json","markdown":"https://secwatch.observer/filing/0001558370-23-005150.md","text":"https://secwatch.observer/filing/0001558370-23-005150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/0001558370-23-005150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/fbio-20230330x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:08:15.545853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0a08636d66a0533d5e6b0348fc50cfe9340e569","claim":"Fortress Biotech, Inc. reported full-year ended December 31, 2022 results: revenue $75.7 million.","evidence_excerpt":"We also generated record consolidated net revenues of $75.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023005150/0001558370-23-005150-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year ended December 31, 2022"},{"label":"Revenue","value":"$75.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}